DMRA
Damora Therapeutics, Inc.
29.42
1 x 20.47
2 x 35.62
bid
ask
+
2.33
8.60%
10:16 AM
timesize
| Ytd | 27.86% | |
| 1y | 731.07% |
26.29
day range
29.48
2.45
52 week range
38.33
| Open | 27.09 | Prev Close | 27.09 | Low | 26.29 | High | 29.48 | Mkt Cap | 1.81B |
| Vol | 50.37K | Avg Vol | 506.08K | EPS | -2.68 | P/E | N/A | Forward P/E | -12.52 |
| Beta | 1.48 | Short Ratio | 3.49 | Inst. Own | 91.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 23.83 | 200-d Avg | 21.25 | 1yr Est | 43.38 |
| Income Statement | |||
| Operating Expenses | 30.81M | ||
| Research and Development Expense | 23.78M | ||
| Selling, General and Administrative Expense | 7.03M | ||
| Operating Income | -30.81M | ||
| Income Tax Expense | 42.00K | ||
| Net Income | -27.78M | ||
| Net Income Common Stock | -27.78M | ||
| Net Income Common Stock (USD) | -27.78M | ||
| Consolidated Income | -27.78M | ||
| Earnings per Basic Share | -0.62 | ||
| Earnings per Basic Share (USD) | -0.62 | ||
| Earnings per Diluted Share | -0.62 | ||
| Earning Before Interest & Taxes (EBIT) | -27.74M | ||
| Earning Before Interest & Taxes (USD) | -27.74M | ||
| Weighted Average Shares | 34.30M | ||
| Weighted Average Shares Diluted | 34.30M | ||
| Balance Sheet | |||
| Cash and Equivalents | 532.90M | ||
| Cash and Equivalents (USD) | 532.90M | ||
| Current Assets | 535.41M | ||
| Total Assets | 535.44M | ||
| Current Liabilities | 23.81M | ||
| Total Liabilities | 23.84M | ||
| Accumulated Retained Earnings (Deficit) | -515.15M | ||
| Accumulated Other Comprehensive Income | 754.00K | ||
| Shareholders Equity | 511.60M | ||
| Shareholders Equity (USD) | 511.60M | ||
| Assets Non-Current | 34.00K | ||
| Liabilities Non-Current | 27.00K | ||
| Trade and Non-Trade Payables | 819.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 68.00K | ||
| Net Cash Flow from Financing | 295.92M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 275.32M | ||
| Issuance (Purchase) of Equity Shares | 295.92M | ||
| Net Cash Flow from Operations | -20.60M | ||
| Effect of Exchange Rate Changes on Cash | -48.00K | ||
| Share Based Compensation | 3.13M | ||